Skip to main content

Advertisement

Log in

Cost-Effectiveness of Biologics Compared with Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis

  • Clinical Trial Report
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Schoels M, Wong J, Scott DL, et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69:995–1003.

    Article  PubMed  Google Scholar 

  2. Marra CA, Marion SA, Guh DP, et al. Not all “quality-adjusted life years” are equal. J Clin Epidemiol. 2007;60:616–24.

    Article  PubMed  CAS  Google Scholar 

  3. Maetzel A, Li LC, Pencharz J, et al. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis. 2004;63:395–401.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Larry W. Moreland.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Patel, A.M., Lupash, D., Chew, D. et al. Cost-Effectiveness of Biologics Compared with Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. Curr Rheumatol Rep 13, 381–382 (2011). https://doi.org/10.1007/s11926-011-0197-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-011-0197-3

Keywords

Navigation